Actuate Therapeutics, Inc. Secures $17.25M Investment

Actuate Therapeutics, Inc. has raised $17,250,000 in new investment capital. The clinical-stage biopharmaceutical company is focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. This funding round provides Actuate with additional resources to advance its pipeline and operations. The company's lead investigational drug, elraglusib, is a novel GSK-3β inhibitor. It targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib achieves this through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). The drug may also mediate anti-tumor immunity by regulating multiple immune checkpoints and immune cell function, highlighting its broad potential in oncology. This recently secured capital is intended to advance Actuate Therapeutics' clinical programs for elraglusib. The investment will support ongoing research and the progression of its therapeutic candidates through various clinical stages. The successful completion of this funding round underscores the continued investor interest in companies developing novel approaches to address unmet needs in cancer treatment. Actuate Therapeutics plans to utilize these funds for key growth initiatives, including the further development of its lead asset. The company is strategically positioned to continue its efforts in bringing innovative therapies to patients battling challenging and aggressive forms of cancer.